Biomarkers for Alzheimer's disease early diagnosis

E Ausó, V Gómez-Vicente, G Esquiva - Journal of Personalized Medicine, 2020 - mdpi.com
Alzheimer's disease (AD) is the most common cause of dementia, affecting the central
nervous system (CNS) through the accumulation of intraneuronal neurofibrillary tau tangles …

Tear biomarkers in Alzheimer's and Parkinson's diseases, and multiple sclerosis: implications for diagnosis (systematic review)

A Król-Grzymała, E Sienkiewicz-Szłapka… - International Journal of …, 2022 - mdpi.com
Biological material is one of the most important aspects that allow for the correct diagnosis of
the disease, and tears are an interesting subject of research because of the simplicity of …

Diagnostic biomarkers in tear fluid: from sampling to preanalytical processing

F Bachhuber, A Huss, M Senel, H Tumani - Scientific reports, 2021 - nature.com
Tear fluid is receiving growing attention as a source for novel diagnostic biomarkers.
Multiple techniques are available for its collection and impact the composition of acquired …

Association of tear fluid amyloid and tau levels with disease severity and neurodegeneration

M Gijs, IHGB Ramakers, PJ Visser, FRJ Verhey… - Scientific reports, 2021 - nature.com
There has been increasing interest in finding non-invasive biomarkers for
neurodegenerative diseases such as Alzheimer's disease (AD). This observational study …

Body fluid biomarkers for Alzheimer's disease—an up-to-date overview

AF Bălașa, C Chircov, AM Grumezescu - Biomedicines, 2020 - mdpi.com
Neurodegeneration is a highly complex process which is associated with a variety of
molecular mechanisms related to ageing. Among neurodegenerative disorders, Alzheimer's …

Tear film microRNAs as potential biomarkers: A review

J Altman, G Jones, S Ahmed, S Sharma… - International journal of …, 2023 - mdpi.com
MicroRNAs are non-coding RNAs that serve as regulatory molecules in a variety of
pathways such as inflammation, metabolism, homeostasis, cell machinery, and …

MicroRNA networks in cognition and dementia

GS Blount, L Coursey, J Kocerha - Cells, 2022 - mdpi.com
The change from viewing noncoding RNA as “junk” in the genome to seeing it as a critical
epigenetic regulator in almost every human condition or disease has forced a paradigm shift …

Advances in proteomic and metabolomic profiling of neurodegenerative diseases

A Schumacher-Schuh, A Bieger, WV Borelli… - Frontiers in …, 2022 - frontiersin.org
Proteomics and metabolomics are two emerging fields that hold promise to shine light on the
molecular mechanisms causing neurodegenerative diseases. Research in this area may …

[HTML][HTML] Recent evidence in epigenomics and proteomics biomarkers for early and minimally invasive diagnosis of Alzheimer's and Parkinson's diseases

S Mayo, J Benito-León, C Peña-Bautista… - Current …, 2021 - ncbi.nlm.nih.gov
Background: Alzheimer's (AD) and Parkinson's diseases (PD) show deposits of improperly
folded modified proteins. Protein expression mechanisms are involved since the early …

[HTML][HTML] Genome-wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsy

GP Brennan, S Bauer, T Engel… - Neurobiology of …, 2020 - Elsevier
Epilepsy diagnosis is complex, requires a team of specialists and relies on in-depth patient
and family history, MRI-imaging and EEG monitoring. There is therefore an unmet clinical …